PDCD1 and neoplasm: In the adaptive, non-comparative phase II TONIC trial, Voorwerk and coworkers investigated multiple strategies (e.g., radiation, low-dose cyclophosphamide, cisplatin, doxorubicin) to make the tumor microenvironment more sensitive to PD-1 blockade with nivolumab in 67 patients with advanced TNBC [63].